These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37840886)

  • 1. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
    Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
    Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
    Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
    Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
    Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report.
    Li R; Liu X; Xu Y; Zhao J; Zhong W; Gao X; Chen M; Wang M
    Thorac Cancer; 2024 Nov; 15(32):2339-2343. PubMed ID: 39343987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.
    Meng Y; Zhou W; Li C; Zhou X; Li X; Li L; Fu Q; Huang J; Yue Y; Shen X; Yang L; Wang M
    Front Oncol; 2024; 14():1383964. PubMed ID: 39015492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
    Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment.
    Huang S; Li L; Yan N; Zhang H; Guo Q; Guo S; Geng D; Liu X; Li X
    Front Oncol; 2024; 14():1331387. PubMed ID: 38706592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
    Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
    Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report.
    Makimoto G; Shimonishi A; Ohashi K; Ninomiya K; Higo H; Kato Y; Fujii M; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Case Rep Oncol; 2022; 15(2):494-498. PubMed ID: 35702678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
    Sohn SH; Sul HJ; Kim BJ; Zang DY
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of
    Kashizaki F; Okazaki S; Tsuchiya N; Chen H; Koizumi H; Takahashi K
    AME Case Rep; 2024; 8():42. PubMed ID: 38711889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
    Hu X; Cui X; Wang Z; Liu Y; Luo Y; Zhong W; Zhao H; Yao M; Jiang D; Wang M; Chen M; Zheng X; Ding L; Wang Y; Yuan X; Wu P; Hu B; Han X; Shi Y
    BMC Cancer; 2023 Apr; 23(1):331. PubMed ID: 37041472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
    Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
    Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With
    Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A
    JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
    Veillon R; Sakai H; Le X; Felip E; Cortot AB; Smit EF; Park K; Griesinger F; Britschgi C; Wu YL; Melosky B; Baijal S; Jr GC; Sedova M; Berghoff K; Otto G; Paik PK
    Clin Lung Cancer; 2022 Jun; 23(4):320-332. PubMed ID: 35466070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
    Baba K; Tanaka H; Sakamoto H; Shiratori T; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Tasaka S
    Thorac Cancer; 2019 Feb; 10(2):369-372. PubMed ID: 30600919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
    Tian J; Lin Z; Chen Y; Fu Y; Ding Z
    Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.